We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.61%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$870M
AUM Growth
-$103M
Cap. Flow
-$99.3M
Cap. Flow %
-11.41%
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$31.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$18.9M
3
DXCM icon
DexCom
DXCM
+$12.6M
4
COO icon
Cooper Companies
COO
+$10.8M
5
ELV icon
Elevance Health
ELV
+$10.4M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$24.2M
2
MRK icon
Merck
MRK
+$22.8M
3
CI icon
Cigna
CI
+$15.1M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$14.7M
5
BSX icon
Boston Scientific
BSX
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IQV icon
51
IQVIA
IQV
$40B
$3.88M 0.45%
22,000
-7,000
-24% -$1.36M
JANX icon
52
Janux Therapeutics
JANX
$1B
$3.82M 0.44%
141,627
-28,373
-17% -$1.07M
EHC icon
53
Encompass Health
EHC
$12.5B
$3.79M 0.44%
37,400
-18,600
-33% -$1.82M
AKRO
54
DELISTED
Akero Therapeutics
AKRO
$3.74M 0.43%
+92,500
New +$3.92M
NUVL
55
DELISTED
Nuvalent
NUVL
$3.72M 0.43%
52,500
-20,000
-28% -$1.56M
MIRM icon
56
Mirum Pharmaceuticals
MIRM
$6.05B
$3.32M 0.38%
73,755
– –
BNTX icon
57
BioNTech
BNTX
$23.2B
$3.26M 0.37%
35,750
-17,000
-32% -$1.9M
KRYS icon
58
Krystal Biotech
KRYS
$9.71B
$3.2M 0.37%
17,750
-6,000
-25% -$1.01M
MRUS
59
DELISTED
Merus
MRUS
$3.14M 0.36%
74,500
– –
RARE icon
60
Ultragenyx Pharmaceutical
RARE
$2.65B
$2.97M 0.34%
+82,000
New +$3.41M
NRIX icon
61
Nurix Therapeutics
NRIX
$2.68B
$2.96M 0.34%
249,336
-40,664
-14% -$680K
MRK icon
62
Merck
MRK
$321B
$2.96M 0.34%
33,000
-244,500
-88% -$22.8M
ACLX
63
DELISTED
Arcellx
ACLX
$2.85M 0.33%
43,500
– –
INSP icon
64
Inspire Medical Systems
INSP
$1.74B
$2.55M 0.29%
16,000
-134,041
-89% -$24.2M
IONS icon
65
Ionis Pharmaceuticals
IONS
$9.35B
$2.44M 0.28%
81,000
-131,500
-62% -$4.31M
VKTX icon
66
Viking Therapeutics
VKTX
$3.98B
$2.42M 0.28%
100,000
+10,000
+11% +$316K
DNTH icon
67
Dianthus Therapeutics
DNTH
$6.15B
$2.3M 0.26%
126,627
+12,627
+11% +$278K
PRVA icon
68
Privia Health
PRVA
$2.83B
$2.2M 0.25%
98,189
-23,000
-19% -$534K
IOVA icon
69
Iovance Biotherapeutics
IOVA
$2.91B
$2.16M 0.25%
647,827
-587,621
-48% -$3.03M
XNCR icon
70
Xencor
XNCR
$1.62B
$2.08M 0.24%
195,750
– –
BRKR icon
71
Bruker
BRKR
$8.67B
$1.77M 0.2%
42,315
+6,000
+17% +$312K
MLTX icon
72
MoonLake Immunotherapeutics
MLTX
$1.42B
$1.76M 0.2%
+45,000
New +$1.94M
ESPR
73
DELISTED
Esperion Therapeutics
ESPR
$1.54M 0.18%
1,066,495
-848,505
-44% -$1.56M
INMB icon
74
INmune Bio
INMB
$56.6M
$1.39M 0.16%
178,284
– –
DNLI icon
75
Denali Therapeutics
DNLI
$3.96B
$1.36M 0.16%
+100,000
New +$1.92M
1 2
3
4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rhenman & Partners Asset Management held 104 positions worth $870M, down 11% from $973M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $99.3M in Q1 2025, closing 10 positions and reducing 55 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Bristol-Myers Squibb worth $19.8M.

  • Rhenman & Partners Asset Management's largest Q1 2025 buy was Bristol-Myers Squibb: 325,000 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Glaukos in Q1 2025, an estimated $31.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2025 reduction was Inspire Medical Systems, cutting an estimated $24.2M.
  • Rhenman & Partners Asset Management fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $14.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $870M portfolio in Q1 2025.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 10 in Q1 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 11% quarter-over-quarter to $870M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2025, filed 14 May 2025.